日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of Proteinuria on Renal Outcomes in the BALANCE Trial

蛋白尿对 BALANCE 试验中肾脏结局的影响

Wallace, Eric L; Wanner, Christoph; Piotti, Giovanni; Lee, David; Koulinska, Irene; Chertkoff, Raul; Warnock, David G

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies

一项 III 期开放标签临床试验,评估每 4 周一次的培尼加糖苷酶 alfa 对既往接受过其他酶替代疗法治疗的法布里病成人患者的疗效。

Holida, Myrl; Linhart, Aleš; Pisani, Antonio; Longo, Nicola; Eyskens, François; Goker-Alpan, Ozlem; Wallace, Eric; Deegan, Patrick; Tøndel, Camilla; Feldt-Rasmussen, Ulla; Hughes, Derralynn; Sakov, Anat; Rocco, Rossana; Almon, Einat Brill; Alon, Sari; Chertkoff, Raul; Warnock, David G; Waldek, Stephen; Wilcox, William R; Bernat, John A

Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity

对评论的回应:在患有法布里病且肾功能恶化的患者中,培尼加糖酶α与阿加糖酶β的头对头试验:为期2年的随机III期BALANCE研究结果——免疫原性测定

Warnock, David G; Wallace, Eric L

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

在患有法布里病且肾功能恶化的患者中,培尼加糖酶α与阿加糖酶β的头对头试验:来自为期2年的随机III期BALANCE研究的结果

Wallace, Eric L; Goker-Alpan, Ozlem; Wilcox, William R; Holida, Myrl; Bernat, John; Longo, Nicola; Linhart, Aleš; Hughes, Derralynn A; Hopkin, Robert J; Tøndel, Camilla; Langeveld, Mirjam; Giraldo, Pilar; Pisani, Antonio; Germain, Dominique Paul; Mehta, Ankit; Deegan, Patrick B; Molnar, Maria Judit; Ortiz, Damara; Jovanovic, Ana; Muriello, Michael; Barshop, Bruce A; Kimonis, Virginia; Vujkovac, Bojan; Nowak, Albina; Geberhiwot, Tarekegn; Kantola, Ilkka; Knoll, Jasmine; Waldek, Stephen; Nedd, Khan; Karaa, Amel; Brill-Almon, Einat; Alon, Sari; Chertkoff, Raul; Rocco, Rossana; Sakov, Anat; Warnock, David G

Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study

美国黑人和白人罹患慢性肾脏病的风险因素:REGARDS 研究

Cheung, Katharine L; Crews, Deidra C; Cushman, Mary; Yuan, Ya; Wilkinson, Katherine; Long, D Leann; Judd, Suzanne E; Shlipak, Michael G; Ix, Joachim H; Bullen, Alexander L; Warnock, David G; Gutiérrez, Orlando M

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease

Lyso-Gb3 与法布里病患者的不良长期预后相关

Nowak, Albina; Beuschlein, Felix; Sivasubramaniam, Visnuka; Kasper, David; Warnock, David G

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study

了解和改善法布里病:一项关键性3期研究的理论基础和设计以及一项患者报告结局验证研究的结果

Wanner, Christoph; Kimonis, Virginia; Politei, Juan; Warnock, David G; Üçeyler, Nurcan; Frey, Aline; Cornelisse, Peter; Hughes, Derralyn

A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm

一种利用机器学习算法识别法布里病高风险患者的新方法

Jefferies, John L; Spencer, Alison K; Lau, Heather A; Nelson, Matthew W; Giuliano, Joseph D; Zabinski, Joseph W; Boussios, Costas; Curhan, Gary; Gliklich, Richard E; Warnock, David G

Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury

比较静态和动态基线肌酐替代指标在定义急性肾损伤中的应用

Warnock, David G; Neyra, Javier A; Macedo, Etienne; Miles, Ayme D; Mehta, Ravindra L; Wanner, Christoph

Current and Investigational Therapeutics for Fabry Disease

法布里病的现有疗法和研究性疗法

Felis, Andrew; Whitlow, Michael; Kraus, Abigayle; Warnock, David G; Wallace, Eric